Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Stephen V. Liu, Leora Horn, Jong Seok Lee et al.|Journal of Clinical Oncology|2021Cited by 818
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialMary O’Brien, Solange Peters, Luis Paz‐Ares et al.|The Lancet Oncology|2022Cited by 738
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung CancerJunghoon Shin, Jong Seok Lee|Cancer Research and Treatment|2018Cited by 110
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Stephen V. Liu, Rafał Dziadziuszko et al.|Lung Cancer|2024Cited by 66
Weekly Docetaxel in Combination With Capecitabine in Patients With Metastatic Gastric CancerJong Ho Chun, Jae-Moon Bae, Hark Kyun Kim et al.|American Journal of Clinical Oncology|2005Cited by 55